A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy.

BACKGROUND Pauci-immune vasculitis is a heterogeneous disorder with an unfavourable prognosis. Renal involvement is frequently observed in antineutrophil cytoplasm autoantibody (ANCA)-associated small-vessel vasculitis and is an important cause of end-stage renal disease (ESRD). Renal replacement therapy (RRT) is frequently required. Although better prognosis under dialysis is well known, the long-term follow-up of pauci-immune renal vasculitis with RRT is rarely reported. METHODS We described 24 patients with pauci-immune vasculitis and requirement of dialysis who were admitted in our institutions from January 1989 to December 2008. Mean age was 65 ± 12 years at the beginning of dialysis. There were 12 males and 12 females. Patients with Wegener's granulomatosis, Churg-Strauss syndrome or evidence of anti-glomerular basement membrane were excluded. The study group was formed by patients with a diagnosis of necrotizing extracapillary glomerulonephritis and microscopic polyangiitis. RESULTS The distribution according to ANCAs was 14 p-ANCA (58%), 5 c-ANCA (21%) and 5 ANCA-negative (21%) pauci-immune renal vasculitis. Pulmonary renal syndrome (PRS) was observed in 10 patients at the onset of vasculitis. Corticosteroids and daily cyclophosphamide were administered to 18 patients, and one patient had intravenous cyclophosphamide. Five patients received isolated corticosteroid therapy. Early reduction in cyclophosphamide dosage was required in five patients due to leucopaenia. Mean follow-up after first dialysis was 89 ± 66 months (range 2-208). Twenty patients were included in haemodialysis (HD), and four patients were included in peritoneal dialysis (PD). At the end of the study, nine patients had received a cadaveric kidney transplant (KT). Relapses rate after the onset of dialysis was 0.03 episode/patient/year. PRS-associated relapses after beginning dialysis were observed in four patients. Main therapy in relapses was also corticosteroids and cyclophosphamide. Survival rates for year 1, 2 and 5 was 91%, 91% and 85%, respectively. Overall mortality at the end of the study was 31.8%. Five patients died in the PRS group, but only one death was associated with progressive pulmonary fibrosis. Higher mortality was observed in PRS vasculitis present at the onset of RRT (50% vs 16.7%, P = NS). Better outcome in patients who received a renal transplantation was observed (88.8% vs 53.8%, P = NS). Conclusions. Despite a low number of patients in this series, pauci-immune vasculitis prognosis under dialysis seems equal to other causes of chronic kidney disease. This study observed a low rate of relapses after beginning dialysis. Poor prognosis is related to severe complications at the beginning of RRT. Today, kidney transplantation is an important therapeutic option for these patients.

[1]  Yichun Hu,et al.  The clinical course of ANCA small-vessel vasculitis on chronic dialysis. , 2009, Kidney international.

[2]  P. Nachman Vasculitis Syndromes: Which maintenance therapy for ANCA vasculitis? , 2009, Nature Reviews Nephrology.

[3]  E. Mirapeix,et al.  Vasculitis syndromes: LAMP-2 illuminates pathogenesis of ANCA glomerulonephritis , 2009, Nature Reviews Nephrology.

[4]  C. Savage,et al.  ANCA-associated vasculitis: from bench research to novel treatments , 2009, Nature Reviews Nephrology.

[5]  L. Mouthon,et al.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. , 2008, The New England journal of medicine.

[6]  J. Ballarin,et al.  [Management of immune suppression in systemic diseases affecting the kidney]. , 2008, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[7]  P. Seo,et al.  Renal Transplantation in the ANCA‐Associated Vasculitides , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  S. Quaglini,et al.  The Long‐Term Prognosis of Renal Transplant in Patients With Systemic Vasculitis , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  C. Savage,et al.  Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  M. Stegall,et al.  Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. , 2007, Kidney international.

[11]  Su-xia Wang,et al.  Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis. , 2007, Journal of the American Society of Nephrology : JASN.

[12]  P. Christaki,et al.  Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: a single-center experience. , 2005, Journal of nephrology.

[13]  J. Stone,et al.  The antineutrophil cytoplasmic antibody-associated vasculitides. , 2004, The American journal of medicine.

[14]  H. Rupprecht,et al.  ANCA-associated vasculitis with renal involvement: an outcome analysis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[16]  D. Adu,et al.  Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  C. Pusey,et al.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  B. Rozman,et al.  Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  J. Jennette Rapidly progressive crescentic glomerulonephritis. , 2003, Kidney international.

[20]  H. V. van Houwelingen,et al.  Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. , 2002, Kidney international.

[21]  P. Jungers,et al.  Immune System Dysregulation in Uremia: Role of Oxidative Stress , 2002, Blood Purification.

[22]  A. Pani,et al.  Immunosuppressive treatment in dialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  D. Jayne,et al.  Pulmonary renal syndrome: a 4-year, single-center experience. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  C. Savage ANCA-associated renal vasculitis. , 2001, Kidney international.

[25]  S. Chadban,et al.  Glomerulonephritis recurrence in the renal graft. , 2001, Journal of the American Society of Nephrology : JASN.

[26]  K.,et al.  Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. , 1999, Kidney international.

[27]  M. Haubitz,et al.  Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  C. Pusey,et al.  Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. , 1998, Journal of the American Society of Nephrology : JASN.

[29]  J. Ranstam,et al.  Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. , 1998, Journal of the American Society of Nephrology : JASN.

[30]  L. Rostaing,et al.  Outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  E. Böttinger,et al.  The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. , 1996, Archives of internal medicine.

[32]  R. Falk,et al.  Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[33]  R. Falk,et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[34]  R. Gans,et al.  Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. , 1995, Kidney international.

[35]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[36]  D. Adu,et al.  Relapses in patients with a systemic vasculitis. , 1993, The Quarterly journal of medicine.

[37]  E. Ritz,et al.  ANCA in haemodialysis patients. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  C. Pusey,et al.  Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  T. The,et al.  Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre , 1990, The Lancet.

[40]  N. Boyce,et al.  Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.